首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1562329

歐洲人疫苗佐劑市場預測至 2030 年 - 區域分析 - 按類型、應用（流感、肝炎、人類乳突病毒等）和最終用戶

Europe Human Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Type, Application (Influenza, Hepatitis, Human papilloma virus, and Others), and End User

出版日期: 2024年07月04日 | 出版商:

The Insight Partners | 英文 113 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2022年歐洲人用疫苗佐劑市場價值為47233萬美元，預計2030年將達到133800萬美元；預計2022年至2030年複合年成長率為13.9%。

個人化疫苗的崛起推動歐洲人用疫苗佐劑市場

精準或個人化疫苗是歐洲人疫苗佐劑市場的成長趨勢。這些疫苗針對患者疾病的特定遺傳或分子特徵，有助於生產適合每位患者獨特免疫反應的疫苗。該技術可以潛在地提高疫苗接種的功效和安全性，從而增加人們對治療癌症、傳染病和自體免疫疾病等疾病的個人化疫苗的興趣。

生產個人化疫苗需要能夠增強對這些客製化疫苗的免疫反應的佐劑。佐劑對於刺激免疫系統對疫苗的特定抗原產生有針對性的強大反應至關重要。因此，對能夠有效增強個人化疫苗免疫反應的佐劑的需求不斷增加。近年來，人們非常重視研發工作，以確定並創造能夠有效增強個人化疫苗免疫反應的佐劑。例如，2022 年 12 月，Moderna 和默克宣布推出 mRNA-4157/V940，這是一種在研個人化 mRNA 癌症疫苗，與 KEYTRUDA(R)（pembrolizumab）聯合使用。與單獨使用 KEYTRUDA 相比，mRNA-4157/V940 合併 KEYTRUDA 輔助治療可將復發或死亡風險降低 44%。監管機構和醫療保健組織認知到個人化疫苗在改善公共衛生結果方面的潛力。例如，2023 年1 月，BioNTech 和英國政府簽署了一份影響廣泛的合作備忘錄(MoU)，到2030 年為多達10,000 名患者提供個人化mRNA 癌症免疫療法。的資金，加快個人化疫苗和佐劑監管途徑的措施。因此，擴大開發有效改善個體化疫苗接種的免疫反應的佐劑，從而提高疫苗的功效和安全性。這一趨勢推動了歐洲人類疫苗佐劑市場的大量創新和投資。

歐洲人用疫苗佐劑市場概況

德國是歐洲乃至全球最大的醫藥市場之一。據德國貿易投資總署 (GTAI) 稱，它是歐盟最大的藥品生產基地，擁有約 600 家製藥公司。根據GTAI 的數據，到2022 年，德國的藥品產量將達到約618 億美元（約565 億）。基礎設施、持續成長的當地化學工業，以及高素質的勞動力可用性。同一消息人士稱，2021年德國製藥業研發投資近95億美元（約88億美元），高於其他產業的研發投資金額。德國的醫療保健產業迎合了歐洲最多的人口，是一個極具吸引力的市場，具有巨大的成長機會。預期壽命水準的穩定成長導致慢性病和與年齡相關的疾病的增加。傳染病流行率的增加預計將刺激疫苗接種的需求。例如，根據 ICO/IARC 資訊中心 2023 年 HPV 與癌症報告，德國有 3,660 萬名 15 歲及以上女性面臨 HPV 相關子宮頸癌的風險。此外，德國的肝炎盛行率很高。由於傳染病的流行，健康意識的提高進一步增加了消費者對藥物、疫苗和療法的需求。因此，隨著製藥公司醫藥研發領域的蓬勃發展以及傳染患者病率的不斷上升，德國對人用疫苗佐劑的需求正在迅速成長。

歐洲人類疫苗佐劑市場收入及 2030 年預測（百萬美元）

歐洲人用疫苗佐劑市場區隔

歐洲人疫苗佐劑市場按類型、應用、最終用戶和國家分類。

根據類型，歐洲人疫苗佐劑市場分為顆粒佐劑、乳液佐劑、組合佐劑等。 2022 年，顆粒助劑領域佔最大的市場佔有率。

從應用來看，歐洲人用疫苗佐劑市場分為流感、肝炎、人類乳突病毒（HPV）等。 2022 年，流感細分市場佔據最大市場。

依最終用戶分類，歐洲人疫苗佐劑市場分為製藥和生技公司、CMO 和 CRO 等。 2022 年，製藥和生物技術公司細分市場佔據最大市場佔有率。

依國家分類，歐洲人疫苗佐劑市場分為德國、英國、法國、義大利、西班牙和歐洲其他國家。 2022年，德國在歐洲人用疫苗佐劑市場佔有率中佔據主導地位。

Creative Biolabs Inc、Croda International Plc、CSL Ltd、Dynavax Technologies Corp、Novartis AG、Novavax Inc、Phibro Animal Health Corp、Seppic SA 和 SPI Pharma Inc 是歐洲人類疫苗佐劑市場上的一些領先公司。

Precision or personalized vaccines are a growing trend in the Europe human vaccine adjuvants market. These vaccines target specific genetic or molecular characteristics of a patient's disease, assisting the production of vaccines tailored to each patient's unique immune response. The technique can potentially improve vaccination efficacy and safety, leading to increased interest in personalized vaccines for treating diseases such as cancer, infectious diseases, and autoimmune disorders.

Adjuvants that can boost the immune response to these tailored vaccines are required to produce personalized vaccines. Adjuvants are essential in stimulating the immune system to develop a targeted and powerful response to the vaccine's specific antigens. As a result, there is an increasing demand for adjuvants that can effectively boost immune responses to personalized vaccines. In recent years, there has been a strong emphasis on R&D efforts to identify and create adjuvants that can effectively increase the immune response to personalized vaccines. For instance, in December 2022, Moderna and Merck announced mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA(R) (pembrolizumab). Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared with KEYTRUDA alone. Regulatory bodies and healthcare organizations recognize personalized vaccines' potential for enhancing public health outcomes. For instance, in January 2023, BioNTech and the UK government signed a wide-reaching Memorandum of Understanding (MoU) to provide up to 10,000 patients with personalized mRNA cancer immunotherapies by 2030. This has increased funding for research and development initiatives in this field and measures to expedite regulatory routes for personalized vaccines and adjuvants. Thus, adjuvants that effectively improve the immune response to personalized vaccinations are increasingly being developed, enhancing vaccine efficacy and safety. This trend drives substantial innovation and investment in the Europe human vaccine adjuvants market.

Europe Human Vaccine Adjuvants Market Overview

Germany is one of the top pharmaceutical markets in Europe and worldwide. According to Germany Trade & Invest (GTAI), it is the biggest pharmaceutical manufacturing location in the European Union, with approximately 600 pharmaceutical companies. According to GTAI, pharmaceutical production volume in Germany reached ~US$ 61.8 billion (~ 56.5 billion) in 2022. Further, the country ranks second in biopharmaceutical production after the US, which is attributed to favorable industrial infrastructure, a sustainably growing local chemicals industry, and highly qualified workforce availability. According to the same source, the pharmaceutical industry in Germany invested almost US$ 9.5 billion (~ 8.8 billion) in R&D in 2021, which is higher than the amounts invested in the R&D of any other industry. Catering to the largest population in Europe, Germany's healthcare sector is a highly attractive market with significant growth opportunities. A steady increase in life expectancy levels has led to a rise in chronic and age-related illnesses. An increase in the prevalence of infectious diseases is expected to fuel the demand for vaccinations. For instance, according to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, Germany has a population of 36.6 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Additionally, Germany has a high prevalence of hepatitis. Improved health awareness due to the prevalence of infectious diseases has further increased consumer demand for drugs, vaccines, and therapies. Thus, the demand for human vaccine adjuvants is growing rapidly in Germany with the flourishing pharmaceutical R&D landscape in pharmaceutical companies, alongside the increasing prevalence of infectious diseases.

Europe Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Europe Human Vaccine Adjuvants Market Segmentation

The Europe human vaccine adjuvants market is categorized into type, application, end user, and country.

Based on type, the Europe human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.

In terms of application, the Europe human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held the largest market share in 2022.

By end user, the Europe human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.

By country, the Europe human vaccine adjuvants market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe human vaccine adjuvants market share in 2022.

Creative Biolabs Inc, Croda International Plc, CSL Ltd, Dynavax Technologies Corp, Novartis AG, Novavax Inc, Phibro Animal Health Corp, Seppic SA, and SPI Pharma Inc are some of the leading companies operating in the Europe human vaccine adjuvants market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Human Vaccine Adjuvants Market - Key Market Dynamics

4.1 Europe Human Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Chronic Diseases
- 4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
- 4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
- 4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
- 4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:

5. Human Vaccine Adjuvants Market - Europe Market Analysis

5.1 Europe Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030
5.2 Europe Human Vaccine Adjuvants Market Forecast Analysis

6. Europe Human Vaccine Adjuvants Market Analysis - by Type

6.1 Particulate Adjuvant
- 6.1.1 Overview
- 6.1.2 Particulate Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
- 6.2.1 Overview
- 6.2.2 Emulsion Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
- 6.3.1 Overview
- 6.3.2 Combination Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Others
- 6.4.1 Overview
- 6.4.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Human Vaccine Adjuvants Market Analysis - by Application

7.1 Influenza
- 7.1.1 Overview
- 7.1.2 Influenza: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
- 7.2.1 Overview
- 7.2.2 Hepatitis: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Human Papilloma Virus (HPV)
- 7.3.1 Overview
- 7.3.2 Human Papilloma Virus (HPV): Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Human Vaccine Adjuvants Market Analysis - by End User

8.1 Pharmaceutical and Biotechnology Companies
- 8.1.1 Overview
- 8.1.2 Pharmaceutical and Biotechnology Companies: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
- 8.2.1 Overview
- 8.2.2 CMOs and CROs: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Human Vaccine Adjuvants Market - Country Analysis

9.1 Europe
- 9.1.1 Europe Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  - 9.1.1.1 Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.1 Germany Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.1.2 Germany Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.1.3 Germany Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.2 UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.1 UK Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.2.2 UK Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.2.3 UK Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.3 France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 France Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.3.2 France Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.3.3 France Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.4 Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.4.1 Italy Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.4.2 Italy Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.4.3 Italy Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.5 Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.5.1 Spain Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.5.2 Spain Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.5.3 Spain Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.6 Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.6.1 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.6.2 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.6.3 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by End User

10. Industry Landscape

10.1 Overview

11. Company Profiles

11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Dynavax Technologies Corp
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 CSL Ltd
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Seppic SA
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 SPI Pharma Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Croda International Plc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Novavax Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Phibro Animal Health Corp
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Creative Biolabs Inc
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. Europe Human Vaccine Adjuvants Market Segmentation
Table 2. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Table 3. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 4. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 5. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
Table 6. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 7. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 8. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 9. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 10. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 11. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 12. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 13. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 14. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 15. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 16. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 17. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 18. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 19. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 20. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 21. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 23. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 24. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 25. Glossary of Terms, Human Vaccine Adjuvants Market

List Of Figures

Figure 1. Europe Human Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Europe Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
Figure 4. Europe Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
Figure 5. Particulate Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Combination Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Europe Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)
Figure 10. Influenza: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Human papilloma virus (HPV): Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Europe Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)
Figure 15. Pharmaceutical and Biotechnology Companies: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. CMOs and CROs: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Europe Human Vaccine Adjuvants Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
Figure 19. Europe Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 20. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 21. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 22. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 23. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 24. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 25. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)